A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Stopped early · Phase 3

Conditions studied: Psoriasis

In brief

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

Key facts

Study ID

NCT03556202

Run by

Eli Lilly and Company

People needed

1936

Starts

2018-09-03

Expected to finish

2022-02-07

Last updated by the study team

2023-03-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must have completed the last visit of an eligible study period of originating study.
• Participant must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential.

You may not qualify if…

• Participant must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study.
• Participant must not have stopped taking mirikizumab during a previous study or if the study investigator thinks restarting mirikizumab would create an unacceptable risk to the participant.

Where it is running

• Zenith Research, Inc. — Beverly Hills, California, United States
• California Dermatology & Clinical Research Institute — Encinitas, California, United States
• First OC Dermatology — Fountain Valley, California, United States
• Keck School of Medicine University of Southern California — Los Angeles, California, United States
• Dermatology Clinical Trials — Newport Beach, California, United States
• San Luis Dermatology & Laser Clinic — San Luis Obispo, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• Univ of Connecticut — Farmington, Connecticut, United States
• Florida Academic Centers Research and Education, LLC — Coral Gables, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Park Avenue Dermatology — Orange Park, Florida, United States
• ForCare Clinical Research — Tampa, Florida, United States
• Dermatologic Surgery Specialists, PC — Macon, Georgia, United States
• Meridian Clinical Research — Savannah, Georgia, United States
• Advanced Clinical Research LLC — Meridian, Idaho, United States
• University Dermatology — Darien, Illinois, United States
• Arlington Dermatology — Rolling Meadows, Illinois, United States
• Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
• The Indiana Clinical Trials Center — Plainfield, Indiana, United States
• The South Bend Clinic Center for Research — South Bend, Indiana, United States
• Forefront Research — Louisville, Kentucky, United States
• DelRicht Research — Baton Rouge, Louisiana, United States
• Dermatology and Skin Cancer Specialists — Rockville, Maryland, United States
• Lawrence J Green, M.D, LLC — Rockville, Maryland, United States
• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.